5 countries call for united EU response to Trump’s drug price threats

Five European governments—Belgium, the Netherlands, Luxembourg, Austria, and Ireland—have called for a unified EU approach to counter U.S. pressure on drug pricing. In a joint statement on Wednesday, the Beneluxa initiative warned against fragmented national responses to threats from the Trump administration and pharmaceutical companies demanding higher medicine prices in Europe. The statement highlights shared structural challenges across member states, emphasizing the need for collaboration. It follows escalating pressure from the U.S., where drug prices are significantly higher than in Europe, particularly in Germany, where costs are around three times lower. The Trump administration has intensified efforts to align European drug pricing with U.S. levels, while also planning to enforce lower domestic prices. The five countries argue that coordinated EU action is essential to prevent disjointed national policies that could undermine collective bargaining power. The Beneluxa initiative’s call comes as pharmaceutical companies and U.S. officials push for European price increases, threatening potential trade or regulatory measures. The group’s statement underscores the risks of individual EU nations responding independently, which could weaken the bloc’s negotiating position. The debate centers on balancing affordability for European patients with global pharmaceutical industry demands. The five countries’ stance reflects broader concerns about maintaining lower drug costs while resisting external pressure.